


The Edward N. & Della L. Thome Memorial Foundation Awards Program in Alzheimer's Disease Drug Discovery Research

Bank of America, N.A., Trustee



INITIAL PROPOSAL DEADLINE:

June 9, 2021

12:00 Noon, U.S. ET

FUNDING PERIOD:

February 1, 2022 – January 31, 2024

AWARD AMOUNT:

Up to ten two-year awards of
\$500,000

APPLICATION MATERIALS:

hria.org/tmf/ThomeAD

QUESTIONS:

LCarver@hria.org

Overview:

The goal of the 2021 Awards Program in Alzheimer's Disease Drug Discovery Research is to support innovative drug discovery research that will lead to improved therapies for individuals suffering from Alzheimer's disease.

Researchers dedicated to the validation and testing of target compounds and therapeutic agents including biologics and small molecules, are encouraged to apply. **Consideration will be given to research focused on pathogenic mechanisms including inflammatory response, synaptic toxicity, neuronal toxicity, and endosomal/lysosomal trafficking defects.**

Basic research or new target discovery, genetic studies, biomarker research, neuro-imaging and clinical studies are currently outside the scope of this Program.

Eligibility:

- Hold a faculty appointment at a non-profit, academic, medical, or research institution in the United States.
- Applicants may not have funding support for a similar project.
- Applicants do not need to be nominated by their institutions.
- United States citizenship is not required; visa documentation is not required.

*The Thome Memorial Foundation
Awards Program is administered by
The Medical Foundation.*



The Medical Foundation
Health Resources in Action